ClearLight Diagnostics LLC has announced that it has completed a $3.5M Series B financing round. Existing investors, a syndicate created by Wiegers Capital Partners, LLC led the round. The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy.

"Continuing our development efforts using the ClearLight technology platform in oncology builds on our initial Proof of Concept work to elucidate the 3-dimensional architecture of the tumor microenvironment. We are pleased with the ongoing support of our investors who have provided further validation of the potential for the ClearLight technology platform," ClearLight CEO, Sarah McCurdy said. The financing follows an initial Series A round of $2.5M for a total of $6M invested in the company.

Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing a product platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is cross-linked to a three-dimensional network of hydrophilic polymers.

The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment.

This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of key biomarker 3D image analysis from lipid-cleared samples.

Source: Story from ClearLight Diagnostics LLC. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.